Prospects for new antibacterials: Can we do better?

Expert Opinion on Investigational Drugs

Volumn 23, Issue 2, 2014, Pages 145-148

  Georgopapadakou, Nafsika H ^a  

^a Anti infectives and Oncology   (United States)

Author keywords

Antibacterial development; Carbapenem resistant enterobacteria; Efflux pumps; Hospital acquired infections; Inactivating enzymes; Multiresistant bacteria; New antibacterials; New targets

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; FOLIC ACID ANTAGONIST; GLYCOPEPTIDE; KETOLIDE; OXAZOLIDINONE DERIVATIVE; TELITHROMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; CLOSTRIDIUM DIFFICILE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84892393378     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.847087     Document Type: Review

References (25)

1. Arias CA, Murray BE. Antibioticresistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009;360:439-43
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12
3. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64(Suppl 1):i3-10
4. Banerjee R, Schecter GF, Flood J, Porco TC. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev Anti Infect Ther 2008;6:713-24
5. Centers for Disease Control and Prevention (CDC). Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep 2009;58(RR-3):1-43
6. Maree CL, Daum RS, Boyle-Vavra S, et al. Community-associated methicillinresistant Staphylococcus aureus isolates and healthcare-associated infections. Emerg Infect Dis 2007;13:236-42 (Pubitemid 46193166)
7. Pootoolal J, Neu J, Wright GD. Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol 2002;42:381-408 (Pubitemid 34160531)
8. Watkins RR, Bonomo RA. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis. Expert Rev Anti Infect Ther 2013;11:543-5
9. Diene SM, Rolain JM. Investigation of antibiotic resistance in the genomic era of multidrug-resistant Gram-negative bacilli, especially Enterobacteriaceae, Pseudomonas and Acinetobacter. Expert Rev Anti Infect Ther 2013; 11:277-96
10. Guzek A, Korzeniewski K, Nitsch-Osuch A, et al. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients. Adv Exp Med Biol 2013;788:109-16
11. Kuijper EJ, van Dissel JT, Wilcox MH. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 2007;20:376-83 (Pubitemid 47026234)
12. Kelly CP. Fecal microbiota transplantation-an old therapy comes of age. N Engl J Med 2013;368:474-5
13. Nathan C, Goldberg FM. Outlook: the profit problem in antibiotic R&D. Nat Rev Drug Discov 2005;4:887-91 (Pubitemid 41637690)
14. Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA 2011;305:1027-8
15. Projan SJ, Bradford PA. Late stage antibacterial drugs in the clinical pipeline. Curr Opin Microbiol 2007;10:441-6 (Pubitemid 350052689)
16. Barnhill AE, Brewer MT, Carlson SA. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob Agents Chemother 2012;56:4046-51
17. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
18. Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf 2012;35(6):447-57
19. O'Neill AJ. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs 2008;17: 297-302 (Pubitemid 351578182)
20. Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008;6: 593-600
21. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med; Published online September 02, 2013
22. Experts in Chronic Myeloid Leukemia (119). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121:4439-42
23. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78:119-46
24. Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Ann NY Acad Sci 2011;1241:153-61
25. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013;13:269-75